Despite the clinical intervention, gliomas recur.6 The time to recurrence is highly variable, and some IDH-mutant LGGs may recur as a low-grade tumor, while others undergo malignant progression and recur as a higher-grade tumor.7 This evidence concerns the gene IDH2 and central nervous system cancer.